This review analyzes genetic polymorphisms and pharmacogenetic aspects in chronic obstructive pulmonary disease, suggesting potential prevention strategies.
Key Points
Genetic research shows that genetic susceptibility increases the risk of chronic obstructive pulmonary disease, highlighting the importance of understanding genetic factors.
Several genetic polymorphisms associated with chronic obstructive pulmonary disease influence therapeutic response, guiding treatment choices based on genetic variations.
Genome-wide association studies have identified chronic obstructive pulmonary disease-associated loci, improving our understanding of disease pathogenesis and predicting severity.
Polygenic risk scores derived from single-nucleotide polymorphisms may enhance predictive medicine and personalized approaches in chronic obstructive pulmonary disease management.